| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K |
| P698 | PubMed publication ID | 9778226 |
| P2093 | author name string | van Riel PL | |
| Haagsma CJ | |||
| van Gestel AM | |||
| P433 | issue | 10 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1845-1850 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Validation of rheumatoid arthritis improvement criteria that include simplified joint counts | |
| P478 | volume | 41 |
| Q91938966 | A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis |
| Q38545293 | A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization |
| Q39088676 | A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure |
| Q35141960 | A close association of body cell mass loss with disease activity and disability in Chinese patients with rheumatoid arthritis |
| Q36994587 | A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis |
| Q64088699 | A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis |
| Q52372777 | A novel gene and pathway-level subtyping analysis scheme to understand biological mechanisms in complex disease: a case study in rheumatoid arthritis. |
| Q35557430 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine |
| Q51630630 | A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. |
| Q36775820 | A randomised, controlled study of outcome and cost effectiveness for RA patients attending nurse-led rheumatology clinics: study protocol of an ongoing nationwide multi-centre study |
| Q37450216 | A simple step test to estimate cardio-respiratory fitness levels of rheumatoid arthritis patients in a clinical setting. |
| Q47318163 | A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis. |
| Q37672814 | Abatacept for the treatment of rheumatoid arthritis: A review |
| Q92857546 | Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register |
| Q42121483 | Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone |
| Q49723275 | Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with infliximab and methotrexate |
| Q35637990 | Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study |
| Q33765844 | Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. |
| Q36923243 | Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. |
| Q33511764 | An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. |
| Q43061720 | Anakinra in the treatment of rheumatic disease |
| Q61799672 | Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort |
| Q89705320 | Anti-inflammatory Diet In Rheumatoid Arthritis (ADIRA)-a randomized, controlled crossover trial indicating effects on disease activity |
| Q36246116 | Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance |
| Q39526831 | Antibodies against M. Bovis 65 KDa Heat Shock Protein and Its P180-188 Epitope in Sera of Patients with Juvenile Idiopathic Arthritis |
| Q41680856 | Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection |
| Q47631468 | Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials |
| Q35552614 | Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis |
| Q35605542 | Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register |
| Q36015069 | Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. |
| Q37471597 | Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds |
| Q37000109 | Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis |
| Q35614010 | Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. |
| Q28271779 | Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort |
| Q51612919 | Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. |
| Q33923459 | B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy |
| Q80463745 | B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection |
| Q87142111 | Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study |
| Q34897514 | Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs |
| Q60044823 | Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study |
| Q42678356 | Can Cyclosporine-A Associated to Methotrexate Maintain Remission Induced by Anti-TNF Agents in Rheumatoid Arthritis Patients? (Cynar Pilot Study) |
| Q37203499 | Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? |
| Q33713206 | Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature |
| Q55512246 | Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. |
| Q39118696 | Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation |
| Q34186473 | Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis |
| Q90457331 | Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study |
| Q28652859 | Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials |
| Q55068670 | Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. |
| Q90140940 | Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries |
| Q90683694 | Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis |
| Q35056149 | Comparing Five Year Out-Come in Two Cohorts of Patients with Early Rheumatoid Arthritis - A BARFOT Study |
| Q36171802 | Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort |
| Q37689754 | Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder |
| Q35901757 | Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis |
| Q37703462 | Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q33495847 | Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response |
| Q46907639 | Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q36125286 | Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis |
| Q30614235 | Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis |
| Q40501745 | Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year. |
| Q35617658 | Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. |
| Q92963153 | Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis |
| Q35840753 | Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis |
| Q37105384 | Determinants of brachial-ankle pulse wave velocity in Chinese patients with rheumatoid arthritis |
| Q36087222 | Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. |
| Q37207909 | Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis |
| Q47778526 | Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. |
| Q54518906 | Discordance between clinical and imaging criteria: assessment by magnetic resonance imaging of the foot of patients with rheumatoid arthritis. |
| Q57169507 | Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice |
| Q47626123 | Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. |
| Q33766248 | Does digital X-ray radiogrammetry have a role in identifying patients at increased risk for joint destruction in early rheumatoid arthritis? |
| Q49370571 | Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus |
| Q89906719 | Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q39328197 | Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis |
| Q80787655 | Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis |
| Q37115728 | Effect of periodontal treatment on the clinical parameters of patients with rheumatoid arthritis: study protocol of the randomized, controlled ESPERA trial |
| Q35559143 | Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. |
| Q42370959 | Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study. |
| Q37356217 | Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis |
| Q35552878 | Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial |
| Q35556066 | Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial |
| Q82906930 | Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity |
| Q33726924 | Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register |
| Q42955604 | Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study. |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q64091799 | Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept |
| Q52665701 | Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. |
| Q37294493 | Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis |
| Q90560827 | Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol |
| Q36133726 | Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis |
| Q35620325 | Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients |
| Q90166578 | Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period |
| Q37345390 | Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis |
| Q36475642 | Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis |
| Q58719858 | Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients |
| Q24647387 | Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis |
| Q42011564 | Great expectations of modern RA treatment |
| Q35247643 | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
| Q42955636 | High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment |
| Q33765931 | High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study |
| Q37116737 | High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial |
| Q36245665 | Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis |
| Q35215520 | Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study |
| Q51503196 | Increased myeloperoxidase plasma levels in rheumatoid arthritis. |
| Q28551216 | Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study |
| Q45877225 | Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change. |
| Q46055310 | Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs |
| Q92633591 | Influence of Ambient Air Pollution on Rheumatoid Arthritis Disease Activity Score Index |
| Q54959070 | Influence of Blue Mussel (Mytilus edulis) Intake on Disease Activity in Female Patients with Rheumatoid Arthritis: The MIRA Randomized Cross-Over Dietary Intervention. |
| Q35553767 | Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis |
| Q41103987 | Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study |
| Q46025003 | Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis? |
| Q88046104 | Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade |
| Q37190006 | Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate |
| Q44247481 | Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? |
| Q64066828 | Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts |
| Q36059579 | Is remission a more realistic goal in psoriatic arthritis? |
| Q42957810 | Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis. |
| Q47780673 | Late infection of total knee arthroplasty inflamed by anti-TNFalpha, Infliximab therapy in rheumatoid arthritis |
| Q55176337 | Lean Mass and Disease Activity are the Best Predictors of Bone Mineral Loss in the Premenopausal Women with Rheumatoid Arthritis. |
| Q97681366 | Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study |
| Q53814762 | Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. |
| Q55018924 | Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. |
| Q49884213 | Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients |
| Q47935954 | Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings |
| Q37704498 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. |
| Q47401668 | Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms |
| Q36204145 | Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. |
| Q55407299 | Male patients with rheumatoid arthritis have an increased risk of osteoporosis: Frequency and risk factors. |
| Q50110839 | Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis |
| Q37536373 | Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). |
| Q38801224 | Memory B Cells and Response to Abatacept in Rheumatoid Arthritis |
| Q84617398 | Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome |
| Q37023883 | Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis |
| Q35638342 | Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study |
| Q36735209 | Metacarpal Index Estimated by Digital X-ray Radiogrammetry as a Tool for Differentiating Rheumatoid Arthritis Related Periarticular Osteopenia |
| Q33837678 | Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib |
| Q39168790 | Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. |
| Q90321904 | Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis |
| Q36639868 | Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials |
| Q26829955 | My treatment approach to rheumatoid arthritis |
| Q37710757 | Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis. |
| Q61628116 | Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data |
| Q47102960 | Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders? |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q80152218 | P wave dispersion in patients with rheumatoid arthritis: its relation with clinical and echocardiographic parameters |
| Q28071844 | Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q30539881 | Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis |
| Q35249630 | Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria |
| Q46325862 | Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. |
| Q28298650 | Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells |
| Q92649030 | Physical activity and sedentary behavior in women with rheumatoid arthritis: a comparison of patients with low and high disease activity and healthy controls |
| Q54605426 | Placental cytokine expression and NF-kappaB activity in women with rheumatic diseases. |
| Q41915915 | Polymorphism of the β3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine |
| Q49915054 | Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients |
| Q37709960 | Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment. |
| Q83140472 | Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis |
| Q36761951 | Premature senescence of T-cell subsets in axial spondyloarthritis |
| Q28743224 | Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression |
| Q35579462 | Psoriatic arthritis assessment tools in clinical trials |
| Q53293292 | Pulmonary involvement in early rheumatoid arthritis patients. |
| Q81198316 | Quality of life in Indian patients with rheumatoid arthritis |
| Q35637041 | Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset |
| Q37020532 | Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. |
| Q59791952 | Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs |
| Q90415263 | Red Cell Distribution Width in Rheumatoid arthritis |
| Q73417418 | Reduced systemic IgG levels against peptidoglycan in rheumatoid arthritis (RA) patients |
| Q33873657 | Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment |
| Q33915665 | Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis |
| Q48198050 | Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. |
| Q53819679 | Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. |
| Q90417661 | Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial |
| Q73521737 | Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity |
| Q59577297 | Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment |
| Q34357253 | Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher brain natriuretic peptide (BNP) levels than patients with inactive disease or healthy control subjects |
| Q35544546 | Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study |
| Q43220265 | Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis |
| Q36382724 | Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. |
| Q37350960 | Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response |
| Q35048395 | Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate |
| Q37690646 | Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials |
| Q35553780 | Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables |
| Q36306270 | Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis |
| Q90324423 | Serum-soluble folate receptor β as a biomarker for the activity of rheumatoid arthritis synovitis and the response to anti-TNF agents |
| Q36584051 | Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry |
| Q35638333 | Sex: a major predictor of remission in early rheumatoid arthritis? |
| Q33576876 | Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort |
| Q43947279 | Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis |
| Q35637474 | Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis |
| Q36930634 | Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response |
| Q44299579 | T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients |
| Q47131694 | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| Q24240905 | TNF-alpha inhibitors for psoriatic arthritis |
| Q57456657 | Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity |
| Q37517356 | Temporal summation of pain and ultrasound Doppler activity as predictors of treatment response in patients with rheumatoid arthritis: protocol for the Frederiksberg hospitals Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort |
| Q35986249 | Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway |
| Q57171084 | Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway |
| Q37374964 | The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial |
| Q42099293 | The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis |
| Q30720251 | The Effect of Socioeconomic Class and Immigrant Status on Disease Activity in Rheumatoid Arthritis: Data from BARFOT, a Multi-Centre Study of Early RA. |
| Q30575606 | The Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RA |
| Q57538743 | The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the Treatment of Immune-Related Diseases: A Systematic Review |
| Q80080632 | The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis |
| Q37353452 | The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. |
| Q37387224 | The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis |
| Q37177587 | The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis |
| Q57213110 | The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial |
| Q55000909 | The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial. |
| Q46081724 | The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. |
| Q40797292 | The metabolic profile in early rheumatoid arthritis: a high prevalence of metabolic obesity |
| Q24564701 | The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial |
| Q90519548 | The prevalence of insomnia and restless legs syndrome among Japanese outpatients with rheumatic disease: A cross-sectional study |
| Q83367094 | The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis |
| Q34724711 | Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial |
| Q40235629 | Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. |
| Q40350291 | Tocilizumab in refractory adult Still's disease |
| Q36513512 | Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study |
| Q34905363 | Treating rheumatoid arthritis to target: the patient version of the international recommendations |
| Q37607063 | Treatment of rheumatoid arthritis: state of the art 2009. |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q41571651 | Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial |
| Q40253542 | Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience |
| Q58112107 | Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28 |
| Q63101754 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e |
| Q53820042 | Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. |
| Q42701821 | Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis |
| Q28545783 | Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis |
| Q36109439 | Variations in the metabolome in response to disease activity of rheumatoid arthritis |
| Q73497690 | Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density |
| Q88186209 | Vitamin D levels and bone mass in rheumatoid arthritis |
| Q47606725 | Vitamin D receptor polymorphisms and expression profile in rheumatoid arthritis Brazilian patients. |
| Q33990812 | Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. |
| Q81329841 | [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)] |
| Q79802311 | [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab] |
| Q84600236 | [How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?] |
| Q46008073 | [How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice]. |
| Q35838512 | ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis |
Search more.